Ozanimod

Overview

Ozanimod is a medication used for the treatment of multiple sclerosis (MS) and inflammatory bowel disease (IBD), specifically ulcerative colitis. Ozanimod is a selective sphingosine 1-phosphate (S1P) receptor modulator. It binds to S1P receptors on lymphocytes (a type of white blood cell), thereby inhibiting their egress from lymph nodes. This action reduces the number of circulating lymphocytes that can cause inflammation in the central nervous system (in the case of MS) or the intestines (in the case of ulcerative colitis). Ozanimod is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is also approved for the treatment of moderate to severe ulcerative colitis in adults who have not responded adequately to conventional therapies.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Neurological Disease | Sphingosine 1 Phosphate Receptor

Product Information

• Catalog No.: B0084-470834
• CAS No.: 1306760-87-1
• Molecular Formula: C23H24N4O3
• Molecular Weight: 404.47
• Purity: ≥95%
• Storage: Store at 2-8 °C, sealed storage, away from moisture
• Solubility: Soluble in DMSO

Source

Original product source